Page 191 - 2021_10-Haematologica-web

HbF rescues dyserythropoiesis in SCD
le cells. J Clin Invest. 1998;101(12):2730-
2740.
37. Franco RS, Yasin Z, Palascak MB, Ciraolo P,
Joiner CH, Rucknagel DL. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood. 2006;108(3):1073-1076.
38. Maier-Redelsperger M, Noguchi CT, de Montalembert M, et al. Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease. Blood. 1994;84(9):3182-3188.
39.Meiler SE, Wade M, Kutlar F, et al.
Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood. 2011;118(4):1109-1112.
40. Ribeil JA, Zermati Y, Vandekerckhove J, et al. Hsp70 regulates erythropoiesis by pre- venting caspase-3-mediated cleavage of GATA-1. Nature. 2007;445(7123):102-105.
41. Noguchi CT, Rodgers GP, Schechter AN. Intracellular polymerization. Disease severi- ty and therapeutic predictions. Ann N Y Acad Sci. 1989;565:75-82.
42. Paikari A, Sheehan VA. Fetal haemoglobin induction in sickle cell disease. Br J
Haematol. 2018;180(2):189-200.
43. Howard J, Hemmaway CJ, Telfer P, et al. A
phase 1/2 ascending dose study and open- label extension study of voxelotor in patients with sickle cell disease. Blood. 2019;133(17):1865-1875.
44. Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381 (6):509-519.
45. Ribeil JA, Hacein-Bey-Abina S, Payen E, et al. Gene therapy in a patient with sickle cell disease. N Engl J Med. 2017;376(9): 848-855.
haematologica | 2021; 106(10)
2719